JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
Last updated: 01 November 2019
A phase 3 study on lung cancer showed that Imfinzi (durvalumab) as a consolidation therapy reduced the risk of the disease progressing by 48 percent.Read more